These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Receptor maturation in pathogenesis and treatment of Tourette syndrome. Friedhoff AJ Adv Neurol; 1982; 35():133-40. PubMed ID: 6959485 [No Abstract] [Full Text] [Related]
43. Tourette syndrome associated with mental retardation: a single-subject treatment study with haloperidol. Rosenquist PB; Bodfish JW; Thompson R Am J Ment Retard; 1997 Mar; 101(5):497-504. PubMed ID: 9083606 [TBL] [Abstract][Full Text] [Related]
44. Clinical efficacy of haloperidol, pimozide, penfluridol, and clonidine in the treatment of tourette syndrome. Shapiro AK; Shapiro E Adv Neurol; 1982; 35():383-6. PubMed ID: 6959514 [No Abstract] [Full Text] [Related]
45. Dopaminergic receptor D5 mRNA expression is increased in circulating lymphocytes of Tourette syndrome patients. Ferrari M; Termine C; Franciotta D; Castiglioni E; Pagani A; Lanzi G; Marino F; Lecchini S; Cosentino M; Balottin U J Psychiatr Res; 2008 Nov; 43(1):24-9. PubMed ID: 18329046 [TBL] [Abstract][Full Text] [Related]
46. [Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol]. Kikumoto O; Okamoto Y; Hayakawa H; Yokota N; Kawai K; Motohashi N; Yamawaki S Yakubutsu Seishin Kodo; 1993 Feb; 13(1):39-42. PubMed ID: 7686319 [TBL] [Abstract][Full Text] [Related]
47. Effects of subchronic exposure to styrene on the extracellular and tissue levels of dopamine, serotonin and their metabolites in rat brain. Gagnaire F; Chalansonnet M; Carabin N; Micillino JC Arch Toxicol; 2006 Oct; 80(10):703-12. PubMed ID: 16518643 [TBL] [Abstract][Full Text] [Related]
52. Treatment of Gilles de la Tourette syndrome with depot neuroleptics. Paolucci S; Buttinelli C; Fiume S; Ciani S; Lenzi GL Acta Neurol (Napoli); 1984 Jun; 6(3):222-4. PubMed ID: 6591768 [No Abstract] [Full Text] [Related]
53. Tourette syndrome. Report of 19 cases. Chen HB; Lu Fei HQ Chin Med J (Engl); 1983 Jan; 96(1):45-50. PubMed ID: 6403311 [No Abstract] [Full Text] [Related]
54. Effects of high dose propranolol in Tourette syndrome. Sverd J; Kupietz S J Clin Psychopharmacol; 1984 Dec; 4(6):359-61. PubMed ID: 6595274 [No Abstract] [Full Text] [Related]
55. Tics of Tourette: important points in management. Daniel AE; Chapel JL J Dev Behav Pediatr; 1981 Dec; 2(4):166-7. PubMed ID: 6947982 [No Abstract] [Full Text] [Related]
56. [Treatment with haloperidol in "maladie des tics" in children]. Lerman P; Nussbaum E Harefuah; 1974 Mar; 86(5):241-2. PubMed ID: 4524559 [No Abstract] [Full Text] [Related]
57. Haloperidol-induced dysphoria in patients with Tourette syndrome. Caine ED; Polinsky RJ Am J Psychiatry; 1979 Sep; 136(9):1216-7. PubMed ID: 289300 [No Abstract] [Full Text] [Related]
58. Possible role of androgens in the pathophysiology of Tourette`s syndrome. A hypothesis with clinical and therapeutic implications. Derakhshan N Neurosciences (Riyadh); 2011 Oct; 16(4):381. PubMed ID: 21983387 [No Abstract] [Full Text] [Related]
59. Treatment of refractory Tourette syndrome with haloperidol decanoate. Clarke DJ; Ford R Acta Psychiatr Scand; 1988 Apr; 77(4):495-6. PubMed ID: 3164570 [TBL] [Abstract][Full Text] [Related]
60. Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist. Uhr SB; Pruitt B; Berger PA; Stahl SM Int Clin Psychopharmacol; 1986 Jul; 1(3):216-20. PubMed ID: 3549873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]